Showing 1241-1250 of 1407 results for "".
- Lumibird Medical Launches New Website Dedicated to Laser Therapies for Each Glaucoma Stagehttps://modernod.com/news/lumibird-medical-launches-new-website-dedicated-to-laser-therapies-for-each-glaucoma-stage/2480684/Lumibird Medical announced the launch of its new website: www.glaucoma-laser-assisted-solutions.com, which details the treatment options at every stage of the disease paradigm: 1. SLT - A first-line treatment for g
- Innovations Will Propel OCT Market to $549 Million in Revenue in 2020https://modernod.com/news/innovations-will-propel-oct-market-to-549-million-in-revenue-in-202/2478426/Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popularity. At the same time promising new technologies on the horizon, such as at-home OCT devices, are g
- DORC Announces FDA Approval of TissueBlue for Staining of the ILM During Vitreoretinal Surgeryhttps://modernod.com/news/dorc-announces-fda-approval-of-tissueblue-for-staining-of-the-ilm-during-vitreoretinal-surgery/2477204/Dutch Ophthalmic Research Centre (DORC) announced it has received FDA approval for TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025%. TissueBlue is the first FDA-approved dye for use as an aid in ophthal
- Panelists Named for “Making Contact Lens Compliance Stick” Eventshttps://modernod.com/news/panelists-named-for-making-contact-lens-compliance-stick-events/2480644/Four highly regarded optometrists have been named as panelists for a pair of Contact Lens Institute online learning events scheduled for March 3. Drs. Chris Lievens, Mark Schaeffer, Bridgitte Shen Lee, and Jason Tu will headline “
- Eyenovia Announces Changes to Board of Directorshttps://modernod.com/news/eyenovia-announces-changes-to-board-of-directors/2480618/Eyenovia announced changes to its Board of Directors. Sean Ianchulev, MD, PhD, Director, Chief Executive Officer and Chief Medical Officer of Eyenovia, has been appointed Chairman Kenneth Lee, Jr., Director, has been named Lead Director
- Sun Ophthalmics to Present E-Posters at AAOpthttps://modernod.com/news/sun-ophthalmics-to-present-e-posters-at-aaopt/2478370/Sun Ophthalmics announced that is will be present several e-posters at the upcoming virtual AAOpt meeting being held this week. Author Presentation October 7, 4-6 pm, Session: Anterior Segment I Toyos M, Shen Lee B, Schechter B, Ogundele A, Gupta P, K
- Staar Surgical Announces Strategic Alliance Agreement with California Center for Refractive Surgery (CCRS)https://modernod.com/news/staar-surgical-announces-strategic-alliance-agreement-with-california-center-for-refractive-surgery-ccrs/2477178/Staar Surgical announced it has entered into a strategic alliance with the California Center for Refractive Surgery (CCRS), a Los Angeles based eye care group with locations in Hancock Park and Sherman Oaks. “Our new multi-clinic alliance with CCRS and its founder Dr. Paul Lee is represent
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- Harrow Launches 'Vevye Access for All' to Reduce Patient Barriers for Dry Eye Disease Treatmenthttps://modernod.com/news/harrow-launches-vevye-access-for-all-reducing-patient-barriers-for-dry-eye-disease-treatment/2482703/Harrow announced 'Vevye Access For All' – a new initiative that aims to reduce patient barriers to dry eye disease treatment. Harrow partnered with specialty pharmacy PhilRx to offer Vevye (cyclosporine ophthalmic solution) 0.1% for eligible patients at $59 a bottle. The g
- Atsena Granted FDA Fast Track Designation for Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-fast-track-designation-for-gene-therapy-to-treat-x-linked-retinoschisis/2482699/Atsena Therapeutics announced that the FDA has granted Fast Track designation for gene therapy product candidate, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of g